Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W McCarthy

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA|January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2026
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA|February 22, 2023
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA Internal Medicine|July 14, 2025
Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|October 1, 2025
Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
JAMA|November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical TrialThomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA|January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2026
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA|February 22, 2023
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA Internal Medicine|July 14, 2025
Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|October 1, 2025
Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
JAMA|November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical TrialThomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Pageof 8